Toxo-pyrimidine phosphate as an inhibitor of bacterial enzyme systems that require pyridoxal phosphate.
Explore the source record for details and available documents.
Bacteria↗
SEARCH · PubMed Health
Results for “PYRIDOXAL PHOSPHATE”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Plasma pyridoxal phosphate concentrations of men fed different levels of vitamin B-6.
The vitamin B-6 status of 12 white, 3 black, and 7 men of other races was evaluated utilizing plasma pyridoxal phosphate concentrations after the males had been on controlled diets for 8 wk. The diets contained averages of 1.22-1.67 mg/d vitamin B-6 as calculated from food composition tables. The actual mean vitamin B-6 content of these diets as analyzed with Saccharomyces uvarum was 0.75-0.98 mg/d; the mean daily protein intakes were 80.8-84.5 g. All subjects had plasma pyridoxal phosphate concentrations (67.6-125.8 nmol/L) well within the normal range; the values of the different race and dietary groups were similar. Vitamin B-6 requirements were satisfied by the consumption of diets analyzed to contain means of 0.75-0.98 mg/d of the vitamin as demonstrated by plasma pyridoxal phosphate levels indicative of adequate status. Dietary vitamin B-6 intakes should be determined by actual analyses when requirements are being determined.
Adult↗
Local electrostatic potentials in pyridoxal phosphate labelled horse heart cytochrome c.
The present work shows the application of an optical label pyridoxal phosphate (PLP) for the experimental determination of local electrostatic potentials in singly substituted cytochromes c modified by pyridoxal phosphate at Lys 79 (PLP-Lys-79-cyt.c) or at Lys 86 (PLP-Lys-86-cyt.c). PLP has also been used to calculate the pKa values of all ionizable groups and the electrostatic potentials in the modified proteins and to analyse their properties. The experimental pKa values for the pyridine nitrogen and phenolic hydroxyl of the bound label were obtained from pH-dependent absorbance and fluorescence measurements, as follows: in PLP-Lys-79-cyt.c for pyridine nitrogen 4.5 (absorbance) and 5.1 (fluorescence), for phenolic hydroxyl 8.6 (absorbance) and 8.3 (fluorescence); in PLP-Lys-86-cyt.c for pyridine nitrogen 4.7 (absorbance) and 5.8 (fluorescence), for phenolic hydroxyl 8.3 (absorbance) and 8.5 (fluorescence). The differences between absorbance and fluorescence data are related to differences in the behaviour of the bound label in the ground and excited electronic states and to intermolecular charge-charge interactions. Molecular modelling was used to generate the atomic co-ordinates of the PLP-modified horse heart cytochrome c necessary for the theoretical calculations of the pKa values and electrostatic potentials.
Animals↗
Inactivation of rhodanese by pyridoxal 5'-phosphate.
Pyridoxal 5'-phosphate and other aromatic aldehydes inactivate rhodanese. The inactivation reaches higher extents if the enzyme is in the sulfur-free form. The identification of the reactive residue as an amino group has been made by spectrophotometric determination of the 5'-phosphorylated pyridoxyl derivative of the enzyme. The inactivation increases with pyridoxal 5'-phosphate concentration and can be partially removed by adding thiosulfate or valine. Prolonged dialysis against phosphate buffer also leads to the enzyme reactivation. The absorption spectra of the pyridoxal phosphate - rhodanese complex show a peak at 410 nm related to the Schiff base and a shoulder in the 330 nm region which is probably due to the reaction between pyridoxal 5'-phosphate and both the amino and thiol groups of the enzyme that appear reasonably close to each other. The relationship betweenloss of activity and pyridoxal 5'-phosphate binding to the enzyme shows that complete inactivation is achieved when four lysyl residues are linked to pyridoxal 5'-phosphate.
Animals↗
A genomic overview of pyridoxal-phosphate-dependent enzymes.
Enzymes that use the cofactor pyridoxal phosphate (PLP) constitute a ubiquitous class of biocatalysts. Here, we analyse their variety and genomic distribution as an example of the current opportunities and challenges for the study of protein families. In many free-living prokaryotes, almost 1.5% of all genes code for PLP-dependent enzymes, but in higher eukaryotes the percentage is substantially lower, consistent with these catalysts being involved mainly in basic metabolism. Assigning the function of PLP-dependent enzymes simply on the basis of sequence criteria is not straightforward because, as a consequence of their common mechanistic features, these enzymes have intricate evolutionary relationships. Thus, many genes for PLP-dependent enzymes remain functionally unclassified, and several of them might encode undescribed catalytic activities. In addition, PLP-dependent enzymes often show catalytic promiscuity (that is, a single enzyme catalyses different reactions), implying that an organism can have more PLP-dependent activities than it has genes for PLP-dependent enzymes. This observation presumably applies to many other classes of protein-encoding genes.
Animals↗
Pyridoxal phosphate inhibition of platelet function.
The effect of pyridoxal phosphate (PLP) on human platelet function in vitro was studied. PLP inhibited adenosine diphosphate (ADP)-induced shape change, aggregation, and the potentiation by ADP of arachidonic acid-induced aggregation. This inhibition could easily be reversed by increasing concentrations of ADP or by removing PLP. The addition of sodium borohydride to PLP-treated platelets produced an irreversible inhibition of ADP aggregation. Thus it is possible that PLP inhibited ADP-induced platelet function by forming a Schiff base with platelet-surface amino groups. PLP also produced a partial inhibition of platelet aggregation to epinephrine, arachidonic acid, A23187, and a dose-dependent inhibition of [14C]serotonin release to epinephrine and arachidonic acid. PLP did not inhibit [14C]serotonin release to A23187, nor did it suppress arachidonic acid-induced malondialdehyde production. The conclusion is drawn that the partial inhibition by PLP of platelet aggregation observed to epinephrine, arachidonic acid, and A23187 resulted from PLP's inhibition of the effect of released ADP.
Adenosine Diphosphate↗
Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion.
Pyridoxal phosphate (PLP), a bioactive form of pyridoxine, dose-dependently (10-1000 microm) inhibited cell proliferation in rat pituitary MMQ and GH3 cells and in mouse AtT-20 cells. After 4 d, MMQ cell numbers were reduced by up to 81%, GH3 cell numbers were reduced by up to 64% (P < 0.05), and AtT-20 cell numbers were reduced by up to 90%. Cell proliferation rates recovered and dose-dependently reverted to control levels after PLP withdrawal. After 4 d, PLP (400 and 1000 microm) decreased [3H]thymidine incorporation by up to 71% (P < 0.05). PLP (400-1000 microm) reduced GH3 cell GH and prolactin secretion and AtT-20 cell ACTH secretion (adjusted for cell number) by approximately 70% after 2 d. The 100 microm PLP also inhibited prolactin secretion (65%, P < 0.05) in primary rat pituitary cells treated for 2 d. PLP decreased the percentage of AtT-20 and GH3 cells in S phase and increased those in G0-G1 phase. Furthermore, PLP induced AtT-20 and GH3 cell apoptosis (28 vs. 6, P < 0.05; 26 vs. 3, P < 0.05, respectively) and dose-dependently reduced content of the antiapoptosis gene Bcl-2. These results indicate that pharmacological doses of PLP inhibit pituitary cell proliferation and hormone secretion, in part mediated through PLP-induced cell-cycle arrest and apoptosis. Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas.
Adenoma↗
[Effects of pyridoxal-phosphate and its 4'- and 5'-substituted analogs on macromolecular structure of Escherichia coli glutamate decarboxylase].
Interactions of pyridoxal phosphate and its analogs (at pH 6.0) with dimeric glutamate apodecarboxylase (E. coli) were examined by spectrophotometric and CD-titration and by gel electrophoresis. It was shown that 5 equivalents of pyridoxal-phosphate fully restore the catalytic activity and optical properties of the enzyme, whereas 3 equivalents of the coenzyme suffice for reconstitution of the hexameric structure. Similar amounts of the 2 nor PLP adn 5'-methtyl PLP restore the hexameric macromolecule. 15 equivalents of pyridoxine phosphate or 54 -- of pyridoxamine phosphate are required for complete saturation of the apoenzymes binding sites and concomitant reconstitution of the hexameric structure. 5'-deoxy-5'-carboxymethyl pyridoxal, 5'-deoxy-5'-phosphonomethyl pyridoxal and cis-5'-deoxy-5'-phosphonomethylen pyridoxal were merely bound to the dimeric apoenzyme, but failed to restore the enzyme's quaternary structure. Pyridoxal, trans-5'-deoxy-5'-posphonomethylen pyridoxal and pyridoxine analogs substituted in position 5' with carboxyl or phosphonyl group did not interact with the apodecarboxylase.
Carboxy-Lyases↗
Changes in albumin/platelet interaction with an artificial surface--due to a antibiotics, pyridoxal phosphate, and lymphocytes.
Protein adsorption and platelet adhesion are two important biological processes arising at the blood prosthetic interface. The effect of certain antibiotics, namely, neomycin, gentamicin, ampicillin, penicillin-G, and streptomycin to modulate the albumin polycarbonate surface interaction was investigated using 125I albumin from a protein mixture in the presence and absence of isolated calf lymphocytes. This study also demonstrated the changes in platelet-surface adhesion with these antibiotics. The effect of pyridoxal phosphate to modulate the red blood cell-mediated platelet-surface attachment was also attempted. It appears from pyridoxal phosphate studies that pyridoxal 5'-phosphate (PLP) could modify the surface-platelet attachment. It also inhibited the fibrinogen-induced platelet adhesion. It seems, the addition of antibiotics to the polymerprotein system increased the level of surface-bound albumin variably whereas lymphocytes incubated in the medium did not affect the surface-albumin concentration with time course. These antibiotics also inhibited the surface-induced platelet adhesion to variable degrees. Our earlier studies have indicated that certain antibiotics or antiplatelet drugs can inhibit the fibrinogen binding to an artificial surface. Therefore, it may be possible that the enhanced albumin-surface concentration or reduced fibrinogen-surface binding, in the presence of these antibiotics, may itself be one of the parameter for a reduced platelet-surface attachment, which may also improve the blood compatibility of the substrate. A better understanding of the mechanism of antibiotics is needed in in vivo conditions to correlate these findings.
Animals↗
Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate.
We determined plasma levels of homocysteine in 584 healthy subjects (380 men and 204 women) from a major utility company in the province of Québec, Canada, and in 150 subjects (123 men and 27 women) with angiographically documented coronary artery disease (CAD) (age < 60 years). Plasma levels of vitamins B12, B6, pyridoxal phosphate (a vitamin B6 derivative), and folate were also determined. Mean homocysteine levels were higher (p < 0.05) in the bottom quartiles for folate, vitamin B12, and pyridoxal phosphate. A significant correlation was noted between homocysteine levels and folate and vitamin B12 levels. No significant correlation was found between plasma homocysteine levels and age, lipids and lipoprotein cholesterol, glucose, and the presence of hypertension or cigarette smoking in healthy subjects or in patients with CAD. Control men had higher homocysteine levels than control women (p < 0.005). Men and women with CAD had higher levels of homocysteine than controls (11.7 +/- 5.8 vs 9.7 +/- 4.9 nmol/ml [p < 0.001] and 12.0 +/- 6.3 vs 7.6 +/- 4.1 nmol/ml, p < 0.01, respectively). Women and men with CAD had similar homocysteine levels. The proportion of patients with CAD having homocysteine levels > 90th percentile of controls was 18.1% for men and 44.4% for women (both p < 0.01). Significantly lower pyridoxal phosphate levels were seen in subjects with CAD, men and women combined (27.7 +/- 29.5 vs 42.1 +/- 38.4 ng/ml, p < 0.005). No significant differences were observed for B12, folate, or total B6.(ABSTRACT TRUNCATED AT 250 WORDS)
Adult↗
[Effect of pyridoxal phosphate on the activity of aminotransferases in different structure-functional regions of the rabbit brain in radiation sickness].
Pyridoxal enzymes of transamination (aspartate aminotransferase, KF 2.6.1.1. and alanine aminotransferase, KF 2.6.1.2) have been studied for their activity in different departments of the rabbit brain under the effect of ionizing radiation and introduction of pyridoxal phosphate. It has been established that the effect of ionizing radiations does not evoke the change in aspartate aminotransferase and alanine aminotransferase activity in different structure-functional departments of the rabbit brain, the decrease of aminotransferases activity in the acute period of the radiation sickness being natural. Introduction of pyridoxal phosphate irradiated animals promotes relative normalization of activity of the enzymes under study.
Alanine Transaminase↗
Cytosinine: pyridoxal phosphate tautomerase, a new enzyme in the blasticidin S biosynthetic pathway.
Cytosinine--the nucleoside portion of blasticidin S--and pyridoxal phosphate were incubated with cell-free extracts of Streptomyces griseochromogenes prepared in D2O. 2H NMR analysis of recovered cytosinine showed it to contain deuterium enrichments at H-4' and H-2'. No exchange was observed with either boiled extract or from cytosinine and pyridoxal phosphate alone. These results reveal the presence of a tautomerase activity that contributes to the net transamination at C-4' in the conversion of cytosylglucuronic acid to blasticidin S, and its discovery supports the role of cytosinine as a biosynthetic intermediate.
Antifungal Agents↗
Pharmacokinetics of a sustained release formulation of pyridoxal phosphate of buflomedil after single or repeated oral doses in healthy volunteers.
The pharmacokinetics of a sustained release (SR) formulation of pyridoxal phosphate of buflomedil (Pirxane retard) has been studied after oral administration to healthy volunteers using among else a gaschromatographic dosage method. After oral administration of 400 mg of the SR formulation, pyridoxal phosphate of buflomedil has a much slower kinetics compared to the normal formulation (tmax:approx. 1.5 h) reaching the maximum plasma concentration, which was about 467 ng/ml, in about 3 h. After 24 h the concentrations were still about 1/10 (48 ng/ml) the maximum value. 24-h urinary excretion was about 21% of the administered dose. Repeated administration of the SR formulation for 7 days in single daily doses of 400 mg gave steady state plasma levels (ca. 250 ng/ml) 12 h after the administration without statistically significant variations. The plasma concentrations of the drug measured daily after reaching the steady state were similar one to the other. The tolerability was very good and no local or systemic side effects of any kind were reported.
Adult↗
Inhibition of phenol sulfotransferase by pyridoxal phosphate.
The biologically abundant cofactor, pyridoxal-5-phosphate (PLP), is a potent inhibitor of bovine phenol (aryl) sulfotransferase (PST). Preincubation of purified enzyme with as little as 1 microM PLP decreased PST activity by 50%. Excess 2-naphthol protected PST from inactivation by PLP, whereas 2-naphthyl sulfate and PAPS were not protective. Although PLP inhibition was apparently competitive with 2-naphthol, a steady-state kinetic Ki value could not be measured due to non-linear Lineweaver-Burk plots in the presence of the inhibitor. Kinetic progress curves revealed that this was due to progressive loss of activity during catalysis. The kinetics of inactivation of PST by PLP were pseudo-first-order and exhibited saturation. The derived KI value for the binding of PLP to PST in the initial reversible step was 23 microM, with a maximal rate of inactivation of 0.077 min(-1). Absorbance spectra of the PST/PLP complex indicated the formation of a Schiff base conjugate, and this is consistent with decreased electrophoretic mobility of the protein-PLP adduct in the presence of dodecyl sulfate only after reduction with borohydride. These results point to the possible regulation of an important detoxification enzyme by a ubiquitous cofactor.
Animals↗
Relationship between blood, liver and brain pyridoxal phosphate and pyridoxamine phosphate concentrations in mice.
Plasma pyridoxal 5'-phosphate (PLP) concentrations are considered to be the most reliable single indicator of vitamin B-6 nutritional status and are thought to reflect tissue PLP and pyridoxamine 5'-phosphate (PMP) levels. We investigated the relationship between dietary level of pyridoxine hydrochloride (PN-HCl) and concentrations of PLP in blood and PLP and PMP in liver and brain of mice. Female heterogeneous stock mice, 60 to 90 d old, were fed purified diets containing 0.5, 1.0, 2.0, 3.0, 5.0, or 7.0 mg PN-HCl/kg diet for 5 wk. PLP and PMP concentrations were determined by a spectrophotometric apotryptophanase assay. PLP content of plasma, erythrocytes, whole blood, liver and brain and PMP levels in liver and brain were highly correlated with dietary level of PN-HCl (r values ranged from 0.81 to 0.94, n per correlation = 32 to 43). By using the entire range of dietary levels of PN-HCl, both plasma and erythrocyte PLP were found to be significantly correlated with tissue PLP and PMP concentrations. For any one dietary level, however, correlations between plasma or erythrocyte PLP and tissue PLP and PMP concentrations were low and nonsignificant. These results suggest that plasma PLP levels may be suitable to determine vitamin B-6 status of populations, but not to reliably predict tissue concentrations of PLP or PMP in individuals.
Administration, Oral↗
Photodynamic properties of pyridoxal phosphate bound to cystathionase-gamma-lyase.
The cofactor pyridoxal phosphate bound through an aldimine linkage to lysine residues of the enzyme cystathionase (L-Cystathione cysteine-lyase (deaminating), EC 4.4.1.1) is very stable to irradiation with light of 420 nm. The catalytic function of the enzyme remains unaffected indicating that the cofactor is not an efficient photosensitizer of essential amino acid residues. This unusual stability of the cofactor to irradiation can be ascribed to the presence of aldimine linkages as demonstrated by studies conducted on model compounds. The binding of a reversible inhibitor (L-allylglycine) to the catalytic site of the enzyme does not facilitate photooxidation of the cofactor. On the contrary, irradiation of the cofactor in the presence of the inhibitor results in photodestruction of the inhibitor.
Allyl Compounds↗
Effects of vitamin B-6 deficiency and 4'- deoxypyridoxine on pyridoxal phosphate concentrations, pyridoxine kinase and other aspects of metabolism in the rat.
Male rats about 100 days old were fed a B-6 deficient diet supplemented with 4'-deoxypyridoxine (1 g/kg diet) and/or pyridoxine hydrochloride (22 mg/kg diet) for 30 to 35 days. Addition of 4'-deoxypyridoxine to the B-6-deficient diet produced greater losses in body weight (P less than 0.05) and thymus weight (P less than 0.01) than in B-6-deficient pair-fed controls. 4'-Deoxypyridoxine combined with a B-6-deficient diet produced no decreases in the concentration of pyridoxal phosphate or pyridoxine kinase in the tissues examined when compared with B-6-deficient controls. Addition of deoxypyridoxine to a diet containing adequate B-6 tended to reduce that absolute weight of the adrenal glands and increased (P less than 0.05) plasma cholesterol compared with animals receiving only vitamin B-6. Compared with the B-6-deficient groups, pyridoxal phosphate concentrations in animals receiving normal B-6 were significantly (P less than 0.01) increased in the liver, muscle and adrenal glands but not in the thymus. In all groups the pyridoxine kinase activity was highest in the adrenal glands (3.6-6.3 pmole pyridoxine phosphate/minute/mg tissue) followed by the liver (1.3-3.7) and thymus (0.7-1.3). These high kinase values and the weight changes suggest an important role for vitamin B-6 in these organs. Recent evidence that pyridoxal phosphate may interact with glucocorticoid receptors raises the possibility that the role of vitamin B-6 in these and other organs may involve metabolic regulation by a mechanism independent of the well-established coenzyme function of this vitamin.
Animals↗
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways.
Vitamin B6 in its active form pyridoxal phosphate is an essential coenzyme of many diverse enzymes. Biochemistry, enzymology and genetics of de novo vitamin B6 biosynthesis have been primarily investigated in Escherichia coli. Database searches revealed that the key enzymes involved in ring closure of the aromatic pyridoxin ring (PdxA; PdxJ) are present mainly in genomes of bacteria constituting the gamma subdivision of proteobacteria. The distribution of DXS, a transketolase-like enzyme involved in vitamin B6 biosynthesis as well as in thiamine and isoprenoid biosynthesis and the distribution of vitamin B6 modifying enzymes (PdxH: oxidase; PdxK: kinase) was also analyzed. These enzymes are also present in the genomes of animals. Two recent papers (Ehrenshaft et al., 1999, Proc. Natl. Acad. Sci. USA. 96: 9374-9378; Osmani et al., 1999, J. Biol. Chem. 274: 23565-23569) show the involvement of an extremely conserved protein (a member of the UPF0019 or SNZ family) found in all three domains of life (bacteria, archaea, eukarya) in an alternative vitamin B6 biosynthesis pathway. Members of this family were previously identified as a stationary phase inducible protein in yeast, as an ethylene responsible protein in plants and in a marine sponge, as a singlet oxygen resistance protein in Cercospora nicotianae and as a cumene hydroperoxide and H2O2 inducible protein in Bacillus subtilis. In yeast, the SNZ protein interacts with another protein called SNO which also represents a member of a highly conserved protein family (called UPF0030 or SNO family). Phylogenetic trees for the DXS, PdxA, PdxJ, PdxH, PdxK, SNZ and SNO protein families are presented and possible implications of the two different vitamin B6 biosynthesis pathways in cellular metabolism are discussed. A radically different view of bacterial evolution (Gupta, 2000, Crit. Rev. Microbiol. 26: 111-131) which proposes a linear rather than a treelike evolutionary relationship between procaryotic species indicates that the gamma subdivision of proteobacteria represents the most recently evolved bacterial lineage. This proposal might help to explain why the PdxA/PdxJ pathway is largely restricted to this subdivision.
Bacterial Proteins↗